



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

March 1, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – February 27, 2021



TOTAL Cases Reported Since 1/22/20

28,355,420

NEW Cases Reported to CDC on 2/27/21

69,876

Change in 7-Day Case Average

+2.1%


Current 7-Day Case Average (2/21/21 - 2/27/21)

67,176

Prior 7-Day Case Average (2/14/21 - 2/20/21)

65,812

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
Current	315,179 (1/8/21)	249,303 (1/11/21)
2nd Peak	75,119 (7/17/20)	67,316 (7/23/20)
1st Peak	42,550 (4/6/20)	31,936 (4/12/20)



New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – February 26, 2021

Patients Currently Hospitalized with COVID on 2/26/21

39,973

New Admissions on 2/26/21

5,222

Peak in New Admissions (1/5/21)

18,006

Change in 7-Day Average of New Admissions


-10.0%

Current 7-Day Average of New Admissions (2/20/21 - 2/26/21)

6,015

Prior 7-Day Average of New Admissions (2/13/21 - 2/19/21)

6,687



Daily Change in COVID-19 Deaths, United States

January 22, 2020 – February 27, 2021

TOTAL Deaths Reported Since 1/22/2020

510,777

NEW Deaths Reported to CDC on 2/27/21

1,828

Change in 7-Day Death Average

+2.4%

Current 7-Day Death Average (2/21/21 - 2/27/21)


1,962

Prior 7-Day Death Average (2/14/21 - 2/20/21)

1,917


Forecasted Total Deaths by 3/20/21

526,000-548,000





WEAR A MASK




STAY 6 FEET APART



AVOID CROWDS



AVOID TRAVEL





U.S. Department of Health & Human Services



U.S. Food and Drug Administration
Protecting and Promoting Your Health

News Release

February 27, 2021

FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine

■ **Janssen COVID-19 Vaccine**




Janssen COVID-19 Vaccine: Phase 3 COV3001 (ENSEMBLE) Study

- **66% vaccine efficacy against moderate to severe/critical COVID-19 across all countries**
 - Protection as of 2 weeks after vaccination
- **72% vaccine efficacy against moderate to severe/critical COVID-19 in the United States**
 - Participants reflected diversity of US population (n > 19,000)
- **85% vaccine efficacy against severe COVID-19 globally, including the United States**
 - Consistent vaccine efficacy against severe disease across all regions
 - Equally high protection in South Africa (n > 6,500) where B.1.351 is highly prevalent (> 95%)
 - Complete protection against COVID-19 related hospitalizations and deaths



Janssen COVID-19 Vaccine Protective Against Emerging SARS-CoV-2 Variants




mRNA Vaccine Approach


mRNA for spike protein of coronavirus



Inject into muscle cells






Muscle cells read the mRNA and make spike protein











Janssen COVID-19 Vaccine Approach

*Adenovirus (Ad26)
Expressing SARS-CoV-2
Spike Protein*

*Intramuscular
injection*



Selected COVID-19 Vaccines

Platform	Developer	Status
Nucleic Acid (mRNA)	  	<ul style="list-style-type: none"> 94% efficacy vs. symptomatic disease → EUA 95% efficacy vs. symptomatic disease → EUA
	Adenovirus Vector	 
Recombinant Protein and Adjuvant		  

Role of NIH and the U.S. Government in the Development and Testing of the Johnson & Johnson (Janssen) COVID-19 Vaccine

- Decades of NIH support of basic, pre-clinical and clinical research to develop the adenovirus 26 (Ad26) vector
- Development of the stabilized pre-fusion spike protein by scientists at the NIAID Vaccine Research Center
- Utilization by J & J of the extensive domestic and international clinical trials network established by NIAID for HIV and Influenza
- Use of the NIAID-funded core laboratory of the HIV Vaccine Trials Network (HVTN) at the Fred Hutchinson Cancer Research Center to perform immunological testing
- Use of the Data and Safety Monitoring Board (DSMB) established by NIAID to monitor the trial
- Extensive Support by BARDA at ASPR of HHS to conduct the trial
- Pre-purchase of hundreds of millions of doses of vaccine by BARDA




The Vaccination Progress Report

7-day average daily doses administered by week as of 2/28/2021



Doses per day





THE WHITE HOUSE
WASHINGTON

WH.GOV